Renaissance Technologies LLC Acquires Shares of 1,451,049 Editas Medicine, Inc. (NASDAQ:EDIT)

Renaissance Technologies LLC bought a new position in Editas Medicine, Inc. (NASDAQ:EDIT) during the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 1,451,049 shares of the company’s stock, valued at approximately $1,843,000. Renaissance Technologies LLC owned approximately 1.76% of Editas Medicine at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Ieq Capital LLC purchased a new position in Editas Medicine during the 4th quarter worth $31,000. Thrive Wealth Management LLC bought a new position in shares of Editas Medicine during the 4th quarter worth $36,000. Intech Investment Management LLC increased its stake in shares of Editas Medicine by 43.1% during the fourth quarter. Intech Investment Management LLC now owns 40,942 shares of the company’s stock valued at $52,000 after buying an additional 12,336 shares during the period. Virtu Financial LLC bought a new stake in shares of Editas Medicine in the fourth quarter valued at about $90,000. Finally, SG Americas Securities LLC lifted its stake in Editas Medicine by 103.7% in the fourth quarter. SG Americas Securities LLC now owns 81,669 shares of the company’s stock worth $104,000 after acquiring an additional 41,573 shares during the period. Institutional investors own 71.90% of the company’s stock.

Editas Medicine Stock Performance

NASDAQ:EDIT opened at $1.54 on Friday. The firm has a 50-day simple moving average of $1.48 and a 200-day simple moving average of $1.83. Editas Medicine, Inc. has a one year low of $0.91 and a one year high of $6.69. The firm has a market cap of $128.91 million, a P/E ratio of -0.60 and a beta of 2.16.

Editas Medicine (NASDAQ:EDIT) last posted its earnings results on Wednesday, March 5th. The company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.16). Editas Medicine had a negative return on equity of 80.13% and a negative net margin of 340.96%. The company had revenue of $30.60 million for the quarter, compared to analysts’ expectations of $37.17 million. During the same quarter in the prior year, the company earned ($0.23) EPS. On average, research analysts predict that Editas Medicine, Inc. will post -2.71 EPS for the current fiscal year.

Editas Medicine Company Profile

Editas Medicine, Inc, a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia.